Work

1591P Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1653

Authors: G. Majhail, E. Xing, P. Savage, J. Krell, M.P. Lythgoe

Institutions: Imperial College Healthcare NHS Trust, Charing Cross Hospital, Royal Sussex County Hospital, Hammersmith Hospital

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Les Laboratories Pierre Fabre, Incyte, European Commission, Astellas Pharma, European Society for Medical Oncology, Servier, Ipsen, Daiichi Sankyo Europe

OpenAlex ID: W4402560250

FWCI: 0.355

Cites:

Cited by: 1

Related to: 10